Medcura Locates to Expanded Research Campus in Riverdale, Maryland
The company intends to manufacture core cGMP compliant hemostatic and wound treatment materials at a scale necessary for commercial launch and in support of the clinical development of implantable devices.
According to company officials the new plant provides an ideal footprint for its expanding business. The manufacturing lab is over four times larger than the Company's prior accommodations and provides strict isolation for the manufacture of commercial materials.
"Expanding into this new plant is just the next stage in our growth arc," said Larry Tiffany, CEO. "These new headquarters give the company state-of-the art manufacturing and R&D labs, while providing a new corporate home where our growing team can build a successful business. By co-locating our product development and manufacturing, we can now more effectively integrate innovations in our chemistry, product design, and means of delivery across our commercial product lines."
Moving into this new facility is quite timely, company officials explained, as it evaluates co-development opportunities with some of the world's largest healthcare companies. These relationships are based on coating Medcura's high-performance materials onto, or infusing them into, market-leading products. By improving the performance of a partner's product line, particularly in bleeding environments where the patient's own clotting ability is compromised, these relationships can deliver increased clinical productivity and patient outcomes through decisive and cost-effective bleeding management in an antibacterial environment.
Company officials said they chose the Discovery District, a growing center for technology and innovation, where high-tech companies can build businesses that develop, manufacture and commercialize disruptive new products. The company said it worked with Terrapin Development and St. John Properties to design and deliver a facility that can house product development, manufacturing and leadership functions that will support commercialization of consumer, clinical, surgical and military applications of its proprietary platform.
"We're thrilled that Medcura has joined a growing group of innovative and entrepreneurial companies that are creating jobs in multiple high-tech industries and are the foundation of our thriving Discovery District," said Ken Ullman, Chief Strategy Officer for Economic Development at the University of Maryland. "Our goal is to foster the rapid growth of companies like Medcura that are started at the University of Maryland and mature to commercialize disruptive new technologies while helping to transform our community."
How are Uncertain Times Altering Company Location Strategies?
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
Infrastructure Investment as an Economic Stimulus Tool
34th Annual Corporate Survey & the 16th Annual Consultants Survey